One important metric to look for in a stock is an 80 or higher Relative Strength Rating. KalVista Pharmaceuticals now clears that threshold, with a jump from 79 to 83 Wednesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary rating identifies share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks typically have an RS Rating of over 80 as they launch their biggest climbs.
KalVista Pharmaceuticals is trying to complete a consolidation with a 16.32 buy point. See if it can break out in volume at least 40% higher than normal.
KalVista Pharmaceuticals showed 0% earnings growth last quarter, while sales growth came in at 0%. Look for the next report on or around Sep. 4.
The company holds the No. 191 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
